Understanding resistance mutations with covalent and non-covalent BTKis 

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses resistance mutations which arise in patients being treated with BTK inhibitors (BTKis), and how these mutations differ when associated with covalent and non-covalent BTKis. Dr Brown comments on the known C481S, L528W and T474I mutations and highlights the need for further investigation into these. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.